Leerink analyst Daina Graybosch reiterated an Outperform rating and $112 price target on BioNTech (BNTX), with the firm saying the company’s deal with Bristol Myers (BMY) is “highly positive” and believes there is continued upside for the stock as investors digest the value Bristol Myers brings to maximizing the value of BNT327. The firm expects less volatility to BioNTech from the COVID vaccine franchise, as the FDA and CDC’s regulatory actions are largely known, but does note the CDC’s Advisory Committee on Immunization Practices June 25-27 meeting has upside and downside potential.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech SE’s Strategic Partnership with Bristol Myers Squibb Boosts Financial Prospects and Reinforces Buy Rating
- BioNTech price target raised to $155 from $151 at Truist
- Bristol deal takes out ‘key’ potential buyer of Summit Therapeutics, says Truist
- Morning Movers: Trump to bump steel tariffs, pharma companies announce deals
- BioNTech and Bristol Myers Squibb Partner for Global Development of BNT327